For instance, the VCU-ART 1, VCU-ART 2, and VCU-ART 3 trials conducted at Virginia Commonwealth University demonstrated that low-dose Anakinra, an interleukin-1 receptor antagonist, administered shortly after acute MI, significantly reduced circulating CRP levels. This evidence concerns the gene CRP and myocardial infarction.